FGF19 and metabolic dysfunction-associated steatohepatitis: To extend the effects of FGF-19 analogs, there is certain evidence relating to the combination of NGM282 and Aldafermin, another engineered FGF-19 analog, in terms of safety and tolerability in healthy volunteers and in patients with NASH.